PCSK9 and cardiovascular disorder: PCSK9 inhibitors in combination with ezetimibe are recommended for patients with ASCVD or those at high risk for cardiovascular disease with plasma LDL-C levels above target in patients with statin intolerance [7] [+, I, A].